Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Iovance Biotherapeutics's operating margin for the twelve months ending Jun 30, 2026 was -92.7%. For fiscal 2025 it was -153.1%, against -240.9% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -153.1% | +87.8 |
| FY2024 | Dec 31, 2024 | -240.9% | +38494.1 |
| FY2023 | Dec 31, 2023 | -38735.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -52.3% | +137.5 |
| Q1 FY2026 | Mar 31, 2026 | -113.5% | +132.3 |
| Q4 FY2025 | Dec 31, 2025 | -84.7% | +32.8 |
| Q3 FY2025 | Sep 30, 2025 | -140.7% | +11.4 |
| Q2 FY2025 | Jun 30, 2025 | -189.8% | +137.9 |
| Q1 FY2025 | Mar 31, 2025 | -245.8% | +16218.9 |
| Q4 FY2024 | Dec 31, 2024 | -117.5% | +25039.4 |
| Q3 FY2024 | Sep 30, 2024 | -152.1% | +25084.8 |
| Q2 FY2024 | Jun 30, 2024 | -327.6% | +45927.0 |
| Q1 FY2024 | Mar 31, 2024 | -16464.6% | – |
| Q4 FY2023 | Dec 31, 2023 | -25156.8% | – |
| Q3 FY2023 | Sep 30, 2023 | -25236.9% | – |
| Q2 FY2023 | Jun 30, 2023 | -46254.6% | – |
See a number that looks wrong?